Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 86, Issue 11, Pages 1990-1997Publisher
WILEY
DOI: 10.1002/jmv.23818
Keywords
AAV vector; gene therapy; epidemiology
Categories
Funding
- Japanese Ministry of Education, Culture, Sports, Science and Technology
- Health, Labour and Science Research Grants for Research on HIV/AIDS
- Research on Intractable Diseases from the Japanese Ministry of Health, Labour and Welfare
- [20591155]
- [21591249]
- [21790920]
- Grants-in-Aid for Scientific Research [24591430] Funding Source: KAKEN
Ask authors/readers for more resources
Pre-existing antibodies against adeno-associated virus (AAV), caused by natural AAV infections, interfere with recombinant AAV vector-mediated gene transfer. We studied the prevalence of neutralizing antibodies against AAV serotypes 1, 2, 5, 8, and 9 in healthy subjects (n=85) and hemophilia patients (n=59) in a Japanese population. For healthy subjects, the prevalence of neutralizing antibodies against AAV serotypes 1, 2, 5, 8, and 9 was 36.5%, 35.3%, 37.6%, 32.9%, and 36.5%, respectively, while that in hemophilia patients was 39.7%, 28.8%, 35.6%, 32.9%, and 27.4%, respectively. There was no difference in the prevalence of neutralizing antibody against each AAV serotype between the healthy subjects and the hemophilia patients. The prevalence of neutralizing antibodies against all AAV serotypes increased with age in both healthy subjects and hemophilia patients. High titers of neutralizing antibodies against AAV2 (1:224) and AAV8 (1:224) were more evident in older individuals (42 years old). Approximately 50% of all screened individuals were seronegative for neutralizing antibodies against each AAV tested, while approximately 25% of individuals were seropositive for each AAV serotype tested. The prevalence of seronegativity for all AAV serotypes was 67.0% (healthy subjects, 68.6%; hemophilia patients, 65.0%) and 18.6% (healthy subjects, 20.5%; hemophilia patients, 15.7%) in young (<42 years old) and older subjects (42 years old), respectively. The findings from this study suggested that young subjects are more likely to be eligible for gene therapy based on AAV vectors delivered via an intravascular route because of the low prevalence of antibodies to AAV capsids. J. Med. Virol. 86:1990-1997, 2014. (c) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available